氟伐他汀治疗非酒精性脂肪性肝病临床疗效及对患者血清炎性因子、肝脏组织脂肪变性及纤维化程度的影响

姜斓; 陈刚; 陈伟; 张莉

doi:10.3969/j.issn.1671-038X.2018.01.08

氟伐他汀治疗非酒精性脂肪性肝病临床疗效及对患者血清炎性因子、肝脏组织脂肪变性及纤维化程度的影响

- 衢州市中医医院消化科, 浙江衢州 324300

详细信息

作者简介:
姜斓,女,本科,主治医师。研究方向:炎症性肠病,消化内镜学及其他消化系统疾病

通讯作者: 姜斓,E-mail:jianglan090@163.com

中图分类号: R575

收稿日期: 2017-08-20

Clinical efficacy of fluvastatin in the treatment of nonalcoholic fatty liver disease and its effects on inflammatory factors,liver steatosis and fibrosis

- Department of Gastroenterology, Quzhou Hospital of Traditional Chinese Medicine, Zhejiang, Quzhou 324300, China

More Information

Corresponding author: JIANG Lan, E-mail: jianglan090@163.com

Received Date: 20 August 2017

摘要

摘要: [目的]研究氟伐他汀治疗非酒精性脂肪性肝病临床疗效以及对患者血清炎性因子、肝脏组织脂肪变性以及纤维化程度的影响。[方法]采用回顾性方式对我院在2015年1月~2017年收治的88例非酒精性脂肪肝患者临床资料进行分析。根据不同治疗方式将患者分成观察组与对照组 (每组44例), 对照组患者采用口服降糖、降血脂药物治疗, 观察组患者在对照组基础上加用氟伐他汀治疗。观察不同治疗方式对2组患者血清炎性因子、肝脏组织脂变性以及纤维化程度的影响。[结果]治疗后观察组患者有效为88.64%, 显著高于对照组[(68.18%), P＜0.05];治疗前2组患者hs-CRP、TNF-α、IL-6、ALT、AST表达水平情况比较无差异 (P＞0.05);治疗后观察组hs-CRP为 (7.54±1.36) mg/L, 显著低于对照组[(14.62±2.57) mg/L, P＜0.05], TNF-α为 (12.62±2.51) ng/L, 显著低于对照组[(28.62±5.47) ng/L, P＜0.05], IL-6为 (12.54±2.34) ng/L, 显著低于对照组[(38.61±6.85) ng/L, P＜0.05], ALT为 (46.59±8.57) U/L, 显著低于对照组[(58.34±10.52) U/L, P＜0.05], AST为 (35.67±8.67) U/L, 显著低于对照组[(44.63±12.52) U/L, P＜0.05];HDL-C、BMI两指标治疗前后比较均无差异 (P＞0.05), 而TG、TC、LDL-C、FBG各指标在治疗前比较无差异 (P＞0.05), 治疗后观察组患者TG为 (1.04±0.26) mmol/L, 显著低于对照组[(2.85±0.66) mmol/L, P＜0.05)];TC为 (3.02±0.46) mmol/L, 显著低于对照组[(5.10±1.12) mmol/L, P＜0.05];LDL-C为 (1.32±0.35) mmol/L, 显著低于对照组[(3.02±1.03) mmol/L, P＜0.05];FBG为 (4.87±1.46) mmol/L, 显著低于对照组[(6.87±1.85) mmol/L, P＜0.05];治疗前2组患者HA、PCⅢ、CⅣ、LN比较差异无统计学意义 (P＞0.05), 治疗后观察组患者HA为 (98.57±21.31) μg/L, 显著低于对照组[(162.57±35.85) μg/L, P＜0.05];PCⅢ为 (86.57±18.57) μg/L, 显著低于对照组[(135.67±27.54) μg/L, P＜0.05];CⅣ为 (84.65±13.57) μg/L, 显著低于对照组[(136.75±22.51) μg/L, P＜0.05];LN为 (74.26±14.53) μg/L, 显著低于对照组[(114.02±20.42) μg/L, P＜0.05];2组患者治疗期间均未出现严重不良反应情况。[结论]氟伐他汀治疗非酒精性脂肪性肝病可减低血清炎症因子、血脂指标以及肝纤维化指标表达水平, 抑制炎症反应, 改善患者血脂代谢异常, 减轻肝脏组织脂肪变性及纤维化程度。
- 氟伐他汀 /
- 非酒精性脂肪肝 /
- 肝脏组织脂肪变性 /
- 血清炎性因子 /
- 纤维化程度
Abstract: [Objective] To investigate the clinical efficacy of fluvastatin in the treatment of nonalcoholic fatty liver disease and its effects on inflammatory factors, liver steatosis and fibrosis.[Methods] The clinical data of 88 patients with nonalcoholic fatty liver disease treated in our hospital from January 2015 to 2017 were retrospectively analyzed.According to the different treatments, the patients were divided into observation group and control group (n=44).The patients in the control group were treated with oral hypoglyce-mic and lipid-lowering drug treatment and the patients in the observation group were given with fluvastatin on the basis of the control group treatment.The effects of different treatment methods on serum inflammatory factors, liver steatosis and fibrosis were observed and compared between the two groups.[Results] After treatment, the effective rate in the observation group was 88.64%, which was significantly higher than that in the control group (68.18%) (P＜0.05).Before treatment, the hs-CRP, IL-6, ALT, TNF-α, AST expression levels had no significant difference between the two groups (P＞0.05).After treatment, the hsCRP in the observation group was (7.54±1.36) mg/L, which was significantly lower than that in the control group[(14.62±2.57) mg/L, P＜0.05].The TNF-αin the observation group was (12.62±2.51) ng/L, which was significantly lower than that in the control group[(28.62±5.47) ng/L, P＜0.05].The IL-6 in the observation group was (12.54±2.34) ng/L, which was significantly lower than that in the control group[(38.61±6.85) ng/L, P＜0.05].The ALT in the observation group was (46.59±8.57) U/L, which was significantly lower than that in the control group[(58.34±10.52) U/L, P＜0.05].The AST in the observation group was (35.67±8.67) U/L, which was significantly lower than that in the control group[(44.63±12.52) U/L, P＜0.05].The HDL-C and BMI showed no significant difference between two groups (P＞0.05).The levels of TG, TC, LDL-C and FBG showed no significant difference between two groups before treatment (P＞0.05).After treatment, the TG in the observation group was (1.04±0.26) mmol/L, which was significantly lower than that in the control group[(2.85±0.66) mmol/L, P＜0.05)].The TC in the observation group was (3.02±0.46) mmol/L, which was significantly lower than that in the control group[(5.10±1.12) mmol/L, P＜0.05].The LDL-C in the observation group was (1.32±0.35) mmol/L, which was significantly lower than that in the control group[(3.02±1.03) mmol/L, P＜0.05].The FBG in the observation group was (4.87±1.46) mmol/L, which was significantly lower than that in the control group[(6.87±1.85) mmol/L, P＜0.05].Before treatment, the HA, PC III, CⅣ, LN showed no significant difference between two groups (P＞0.05).After treatment, the HA in the observation group was (98.57±21.31) g/L, which was significantly lower than the control group[(162.57±35.85) g/L, P＜0.05].The PCIII in the observation group was (86.57±18.57) g/L, which was significantly lower than that in the control group[(135.67±27.54) g/L, P＜0.05].The CⅣin the observation group was (84.65±13.57) g/L, which was significantly lower than that in the control group[(136.75±22.51) g/L, P＜0.05].The LN in the observation group was (74.26±14.53) g/L, which was significantly lower than that in the control group[(114.02±20.42) g/L, P＜0.05].There was no serious adverse reactions in two groups during treatment.[Conclusion] Fluvastatin in the treatment of nonalcoholic fatty liver disease can reduce the serum inflammatory factors, blood lipid index and liver fibrosis index levels and inhibit inflammation, improve abnormal lipid metabolism and relieve liver fatty degeneration and fibrosis degree.
- Fluvastatin /
- nonalcoholic fatty liver disease /
- fatty degeneration of liver tissue /
- serum inflammatory factors /
- fibrosis degree

HTML全文

参考文献(12)

[1]	Haas J T, Francque S, Staels B.Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease[J].Annual Review Physiol, 2016, 78 (1):181-181.
[2]	延华, 鲁晓岚, 高艳琼, 等.西北地区脂肪性肝病的流行病学调查研究[J].中华肝脏病杂志, 2015, 23 (8):622-627.
[3]	刘志军, 张红, 熊玉卿.高血脂患者中氟伐他汀群体药代动力学特征的研究[J].中国临床药理学杂志, 2017, 33 (13):261-262.
[4]	张燕丽, 温凯, 马小惠, 等.他汀类药物对动脉粥样硬化性心血管疾病患者血脂和超敏C-反应蛋白的影响[J].实用临床医药杂志, 2015, 19 (1):196-198.
[5]	罗春华, 李国静, 周军, 等.宜昌市职业人群非酒精性脂肪性肝病流行病学调查及其与代谢综合征相关性研究[J].重庆医学, 2016, 45 (3):390-392.
[6]	Mantovani A, Mingolla L, Rigolon R, et al.Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1diabetes[J].Int J Cardiol, 2016, 225 (4):387-391.
[7]	王婷婷, 庄丽维, 韩继武, 等.非酒精性脂肪性肝病的研究进展[J].现代生物医学进展, 2015, 15 (8):1570-1572.
[8]	Al R M, Silverman M G, Nasir K, et al.The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis:the Multi-Ethnic Study of Atherosclerosis (MESA)[J].Atherosclerosis, 2015, 239 (2):629-629.
[9]	沈静雪, 刘宇, 张盈妍.2型糖尿病合并非酒精性脂肪性肝病患者血清炎性因子水平的变化及意义[J].山东医药, 2015, 59 (37):34-36.
[10]	徐永龙.阿托伐他汀对非酒精性脂肪性肝炎患者肝功能及炎性因子的影响[J].中国中西医结合消化杂志, 2016, 24 (1):17-19.
[11]	余红梅, 刘新云.氟伐他汀对早期糖尿病肾病患者炎症因子及疗效的影响[J].中国药师, 2015, 18 (2):271-272.
[12]	Chong L W, Hsu Y C, Lee T F, et al.Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.[J]Bmc Gastroenterology, 2015, 15 (1):22.